R

Regeneron Pharmaceuticals

Develops biopharmaceutical therapies for serious diseases

Vice President International Medical Affairs

Full-TimePosted on 10/19/2026
€285k - €385k/yr
Expert
MD
Paris, France+3 moreMore locations: Madrid, Spain | Dublin, Ireland | Munich, Germany
HybridHybrid work schedule; approximately 50% international travel required.
Biology & Biotech

About the job

Requirements
  • A medical degree (MD or equivalent) is required; board certification is desirable, and a valid medical license is required as applicable.
  • At least 18 years of progressive industry or relevant experience, including at least 12 years of therapeutic-area experience in biotech or pharma; breadth across multiple therapeutic areas is preferred.
  • Significant Medical Affairs pre-launch and launch experience in major international markets such as Europe, Japan, or Canada.
  • Thorough understanding of the international (ex-US) healthcare environment across major markets.
  • Strong background in drug development and lifecycle management across multiple therapeutic areas.
  • Proven people leadership across large, geographically dispersed teams, including medical directors and Medical Science Liaisons, with a track record of developing talent and making sound talent decisions.
  • Strategic leadership and business acumen, including aligning international activities with global strategy while accounting for individual market nuances.
  • Experience working in matrix, cross-functional, and alliance relationships, and ability to build relationships with key internal and external stakeholders.
  • Strong interpersonal skills, including motivational, negotiation, listening, judgment, analytic, and conflict-management skills.
  • Excellent presentation and communication skills, with fluency in English.
  • Ability to thrive in a fast-paced, rapidly changing environment, work collaboratively and with a solutions-oriented approach, and operate with a start-up mindset in new and evolving markets.
  • Willingness to travel approximately 50% of the time, including internationally.
Responsibilities
  • Represent the organization across international (ex-US) markets for Medical Affairs, spanning the portfolio from pre-launch through launch, lifecycle management, and in-market support.
  • Lead the international Medical Affairs organization across medical strategy, operations, medical communications, and medical information, including direct leadership of Country and Regional Medical Directors.
  • Develop and execute international medical strategies aligned to Global Therapeutic Area Franchise strategies and adapted to local market needs, partnering with Global Franchise Heads and Global Medical Leads to ensure effective localization.
  • Own international Medical Affairs operations, including planning, resourcing, budget, processes, systems, vendor management, and compliance, to enable consistent and efficient execution across regions.
  • Own international medical communications and medical information, ensuring scientific content, publications, congress activity, and medical information responses are accurate, compliant, aligned to global standards, and adapted for local audiences.
  • Operate within the global Medical Affairs operating model, standards, systems, and governance, applying and adapting them in international markets and owning in-market operational execution.
  • Partner with International Commercial, Market Access, Regulatory Affairs, and other senior international leaders to support the portfolio across pre-launch, launch, and lifecycle management.
  • Contribute to global strategy and gather medical insights from international markets to shape global and local medical plans.
  • Support clinical development programs and identify medical centers of excellence to help accelerate the pipeline.
  • Establish and monitor KPIs for international medical performance and operational excellence, and advocate for adequate resources.
  • Engage external medical experts and medical societies to advance scientific and medical understanding, and represent the organization at professional and medical meetings.
  • Ensure appropriate training, expertise, and local stakeholder engagement across direct and indirect markets.
  • Ensure full compliance with corporate standards and applicable government and industry regulations across international markets.
  • Recruit, develop, and retain talent, and foster a strong, collaborative culture across a geographically dispersed team.
Desired Qualifications
  • Board certification is desirable.
  • Breadth across multiple therapeutic areas is preferred.
  • Experience leading or overseeing medical operations, medical communications, and/or medical information.

About the company

R

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi paid $1 billion upfront, with up to $7 billion more for Regeneron's immunology pipeline.
  • Q2 2026 revenue rose 17% to $4.3 billion; Dupixent sales hit $6.0 billion.
  • Libtayo and EYLEA HD both posted record sales in Q2 2026, widening diversification.

What critics are saying

  • EYLEA biosimilar competition starts in January 2027 after Samsung's settlement.
  • Regeneron faces a 2026 SDNY securities class action over the failed fianlimab melanoma trial.
  • Dupixent's patent cliff later this decade threatens the company's biggest profit pool.

What makes Regeneron Pharmaceuticals unique

  • VelocImmune keeps generating partnered immunology assets; Sanofi renewed the alliance on October 1, 2026.
  • Dupixent remains Regeneron's engine, with over 1.5 million patients across nine indications.
  • EYLEA HD conversion shows platform strength; U.S. sales hit $596 million in Q2 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Wellness Program
  • Paid Vacation
  • Equity Awards
  • Annual Bonuses
  • Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

12%

2 year growth

12%
Yahoo Finance
Oct 21st, 2026
Regeneron trades at 19.2x earnings versus Amgen's 27.1x despite similar growth

Regeneron Pharmaceuticals trades at 19.2 times earnings for the four quarters ended June 30, 2026, well below Amgen's 27.1, though both grew revenue at a similar pace. Regeneron's revenue rose 9.3% against Amgen's 9.1%. Amgen has the higher operating margin, at 30.0% against 26.9%. Its shares also gained more over the past year, rising 51.0% against 40.4%. Regeneron's largest drug, EYLEA, is shrinking. Its revenue fell to $2.75 billion in fiscal 2025 from $4.77 billion, and management expects demand to fall further as biosimilars launch. Partners supply about half of revenue, and management expects Sanofi collaboration revenue to rise from fiscal Q3 2026. The next report is expected on or around October 30, 2026.

Yahoo Finance
Oct 19th, 2026
Regeneron's weight loss drugs could challenge Eli Lilly and Novo with 19% weight loss

Regeneron Pharmaceuticals could carve out a place in the fast-growing weight loss market, where Eli Lilly and Novo are expected to stay ahead for about five years. Its drug olatorepatide, licensed from a China-based company, mimics the GLP-1 and GIP hormones, as Lilly's Zepbound does. In a Phase 3 study in China, it led to mean weight loss of up to 19% over 48 weeks, with fewer stomach-related side effects than some rivals. Regeneron still needs US late-stage trials before approval. Its other candidate, trevogrumab, helps patients keep lean mass. In a Phase 2 study alongside Novo's semaglutide, lean mass preservation reached up to 42.5%, against 7.3% with semaglutide plus placebo. Second-quarter revenue rose 17% year over year to $4.3 billion, driven by eczema drug Dupixent.

Yahoo Finance
Oct 14th, 2026
Regeneron's Sanofi repayment ends, setting up a possible revenue boost after $2.2B record quarter

Regeneron Pharmaceuticals may get its next boost from an old deal rather than a new drug. The company finished repaying a balance to its partner Sanofi, and since the third quarter of 2026 it has recorded its full share of profits from their collaboration. Regeneron expects Sanofi collaboration revenue to step up as a result, though that remains a forecast. The repayment cut reported revenue by about $930 million in 2025 and $530 million in the first half of 2026. Revenue from the collaboration already hit a record $2.2 billion in the second quarter. A step-up matching the 2025 loss would add about 6.5% to the company's 2025 revenue of $14.3 billion. Dupixent sales reached $6 billion worldwide in the quarter, up 38% at constant currency, but growth should moderate in the second half.

Asianet News
Oct 13th, 2026
Regeneron's rare disease drug shows zero new abnormal bone growth in extended trial - REGN stock heads for best day in over A month.

Regeneron's rare disease drug shows zero new abnormal bone growth in extended trial - REGN stock heads for best day in over A month. Published: Oct 13 2026, 12:15 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us The firm's Pasatru drug was approved by the FDA in August, after trial results showed at least a 90% reduction in new abnormal bone lesions after 56 weeks. * The Phase 3 Optima trial enrolled 63 adults who received Pasatru or a placebo every four weeks. * A higher dose recorded one disease flare-up, compared with 17 in the placebo group. * The findings were presented at the American Society for Bone and Mineral Research. Regeneron Pharmaceuticals (REGN) reported encouraging long-term results for its recently approved rare disease drug on Monday, with patients showing no new abnormal bone growth during an extended Phase 3 trial. REGN shares were up about 2.8% and heading for their best day in over a month. What did the trial show? Regeneron's Pasatru treats fibrodysplasia ossificans progressiva (FOP), an extremely rare condition in which muscles, tendons and other soft tissues gradually turn into bone. The Phase 3 Optima trial enrolled 63 adults who received Pasatru or a placebo every four weeks. Between weeks 56 and 84, patients taking Pasatru developed zero new abnormal bone lesions, compared with nine in the placebo group. The findings were presented at the American Society for Bone and Mineral Research (ASBMR). Regeneron plans new study for children. The FDA approved Pasatru in August, following earlier trial results showing at least a 90% reduction in new abnormal bone lesions after 56 weeks. European regulators are currently reviewing Pasatru. The drug works by blocking Activin A, a protein involved in abnormal bone formation. Regeneron plans to begin another Phase 3 study, Optima 2, involving children and adolescents later this year. REGN's pipeline includes cancer, eye disease treatments. Beyond Pasatru, Regeneron is expanding its broader drug pipeline, which includes treatments for cancer, eye diseases and inflammatory conditions. The biotech firm recently expanded its partnership with Sanofi (SNY) to develop four new long-acting antibody treatments for inflammatory diseases. Under the deal, Regeneron will receive $1 billion upfront and could earn an additional $7 billion if the treatments meet certain development, regulatory, and sales targets. The companies will share development costs and split future profits equally. The company reported about $17.8 billion in cash and marketable securities as of June 30. Separately, BofA raised its price target on Regeneron to $908 from $891 and kept a 'Buy' rating. This implies a 19% upside from current levels. Retail remains bullish on REGN. Despite the recent run, retail sentiment on Stocktwits surrounding REGN remained 'bullish' over the past 24 hours. The stock is down around 1.4% so far this year, underperforming the broader State Street SPDR S&P Biotech ETF's (XBI) roughly 25% gains. Also read: Microsoft Looks In-House To Power Its AI Ambitions - CEO Nadella Calls It 'Our Biggest Bet Yet On Our Own Silicon' For updates and corrections, email newsroom[at]stocktwits[dot]com.< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

Yahoo Finance
Oct 12th, 2026
Regeneron's Pasatru shows zero new bone lesions in adult FOP patients at 84 weeks

Regeneron Pharmaceuticals said its drug Pasatru (garetosmab-grts) showed sustained results in adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes bone to grow in muscle and connective tissue. The 84-week data from the Phase 3 OPTIMA trial were presented at the American Society for Bone and Mineral Research annual meeting. From week 56 to week 84, patients on Pasatru had no new abnormal bone lesions, against nine for placebo. New flare-ups numbered one on the 10 mg/kg dose, 14 on the 3 mg/kg dose, and 17 on placebo. The trial enrolled 63 adults. Skin and soft tissue infections rose with dose but all resolved, and no patients stopped treatment because of them. The US Food and Drug Administration recently approved Pasatru. A trial in children and adolescents is planned to begin later this year.